Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TRML

Tourmaline Bio Inc

Oct 23 • 04:00PM ET

47.96

-0.01 -0.02 %

Healthcare • Biotechnology • USA • NASD

Peers: XOMA PSTX CYTK ALLO BPMC ONC NBIX SRPT MRNA ALT

| Held by: VTI IWM VXF IWN IBB SCHA VTWO AVSC ARB IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.44	Insider Own	35.42%	Shs Outstand	25.69M	Perf Week	0.13%
Market Cap	1.23B	Forward P/E	-	EPS next Y	-4.04	Insider Trans	0.00%	Shs Float	16.59M	Perf Month	0.44%
Enterprise Value	993.11M	PEG	-	EPS next Q	-0.95	Inst Own	74.40%	Short Float	5.92%	Perf Quarter	142.59%
Income	-88.47M	P/S	-	EPS this Y	-28.14%	Inst Trans	-2.85%	Short Ratio	1.10	Perf Half Y	176.91%
Sales	0.00M	P/B	4.75	EPS next Y	-8.98%	ROA	-28.81%	Short Interest	0.98M	Perf YTD	136.49%
Book/sh	10.09	P/C	5.15	EPS next 5Y	-17.10%	ROE	-29.62%	52W High	48.27 -0.64%	Perf Year	69.44%
Cash/sh	9.31	P/FCF	-	EPS past 3/5Y	43.97% 8.04%	ROIC	-34.13%	52W Low	11.56 314.88%	Perf 3Y	94.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	0.10% 0.19%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	6.66%	Oper. Margin	-	ATR (14)	0.33	Perf 10Y	-
Dividend Ex-Date	Oct 20, 2023	Quick Ratio	24.68	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	89.27	Recom	2.75
Dividend Gr. 3/5Y	- -	Current Ratio	24.68	EPS Q/Q	-31.89%	SMA20	0.13%	Beta	2.30	Target Price	48.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	20.93%	Rel Volume	1.20	Prev Close	47.97
Employees	74	LT Debt/Eq	0.00	Earnings	Aug 13 BMO	SMA200	113.55%	Avg Volume	889.38K	Price	47.96
IPO	May 07, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.54% -	Trades		Volume	1,068,581	Change	-0.02%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-23-25	Initiated	Chardan Capital Markets	Buy	$70
Mar-06-25	Initiated	Wedbush	Outperform	$42
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$50
Nov-11-24	Reiterated	H.C. Wainwright	Buy	$48 → $49
Dec-15-23	Initiated	Jefferies	Buy	$41
Dec-04-23	Resumed	H.C. Wainwright	Buy	$48
Nov-17-23	Initiated	Truist	Buy	$43
Oct-31-23	Initiated	Guggenheim	Buy	$50
Oct-25-23	Initiated	Piper Sandler	Overweight	$65
Oct-20-22	Initiated	H.C. Wainwright	Buy	$18
Jul-05-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$20 → $8

Show Previous Ratings

Oct-16-25 08:50AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug (Zacks)
Sep-10-25 11:06AM	NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline (Zacks)
Sep-09-25 04:06PM	Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense' (Investor's Business Daily) +57.85%
10:36AM	Novartis & Tourmaline, Anglo American & Teck, CoreWeave AI fund (Yahoo Finance Video)
09:07AM	Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion (Investor's Business Daily)
07:28AM	Loading…
07:28AM	This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It. (Barrons.com)
05:39AM	Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range (MarketWatch)
02:02AM	Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal (The Wall Street Journal)
01:03AM	Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG (GlobeNewswire)
Aug-31-25 10:23AM	Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress (GlobeNewswire)
Aug-15-25 09:55AM	Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know (Zacks)
Aug-13-25 07:00AM	Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-28-25 02:15PM	H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results (Insider Monkey)
May-22-25 05:25PM	BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML) (Insider Monkey)
May-20-25 07:30AM	Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease (GlobeNewswire)
04:05PM	Loading…
May-19-25 04:05PM	Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 (GlobeNewswire)
May-02-25 07:30AM	Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -8.68%
Apr-03-25 01:59PM	Tourmaline Bio: We Should Wait For Upcoming Phase 2b Trial Data (Seeking Alpha)
Mar-13-25 07:30AM	Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-07-25 09:41AM	Robinhood initiated, MongoDB downgraded: Wall Streets top analyst calls (TipRanks)
Mar-03-25 07:15AM	Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire) -5.81%
Jan-27-25 07:00AM	Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-10-25 07:30AM	Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker (GlobeNewswire)
Dec-10-24 08:30AM	Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day (GlobeNewswire)
Nov-14-24 07:30AM	Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 (GlobeNewswire)
Nov-12-24 11:00PM	Tourmaline Bio, Inc. Reports Third Quarter Financial Results (TipRanks) -7.63%
Nov-07-24 07:30AM	Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-31-24 07:30AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-15-24 07:30AM	Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 (GlobeNewswire)
Oct-11-24 07:30AM	Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress (GlobeNewswire) -8.48%
07:30AM	Loading…
Oct-08-24 07:30AM	Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board (GlobeNewswire) +6.86%
Sep-03-24 07:45AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:30AM	Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +6.13%
Aug-02-24 04:30PM	Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024 (GlobeNewswire) -8.09%
Jun-27-24 08:05AM	Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer (GlobeNewswire) -5.84%
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
May-23-24 07:10AM	Tourmaline Bio to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 07:00AM	Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial (GlobeNewswire)
May-13-24 01:54PM	TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-02-24 07:00AM	Avalo Therapeutics Appoints Biotech Leaders to Board of Directors (GlobeNewswire) -7.39%
Mar-19-24 02:52PM	TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023 (InvestorPlace)
07:00AM	Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-15-24 08:50AM	Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going (Zacks)
Feb-28-24 08:50AM	Here's What Could Help Tourmaline Bio, Inc. (TRML) Maintain Its Recent Price Strength (Zacks)
Feb-27-24 07:30AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-08-24 08:50AM	What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing' (Zacks)
Feb-01-24 08:00AM	Tourmaline Bio to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 04:01PM	Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-25-24 07:00AM	Tourmaline Bio Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +7.33%
Jan-24-24 04:05PM	Tourmaline Bio Announces Proposed Public Offering of Common Stock (GlobeNewswire) -6.37%
Jan-08-24 07:00AM	Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD) (GlobeNewswire) +9.25%
Dec-15-23 04:00PM	Tourmaline Bio added to the NASDAQ Biotechnology Index (GlobeNewswire) -5.00%
Dec-14-23 07:30AM	Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board (GlobeNewswire)
Nov-01-23 08:00AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-26-23 09:02PM	CEO Sandeep Kulkarni Buys 9650 Shares of Tourmaline Bio Inc (GuruFocus.com) +5.83% +7.03%
Oct-19-23 05:37PM	Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million (GlobeNewswire) -59.93%
Oct-17-23 05:47PM	Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio (GlobeNewswire) -6.00%
Oct-06-23 05:09PM	Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio (GlobeNewswire)
Oct-04-23 08:30AM	New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics (GlobeNewswire)
Jun-22-23 07:30AM	Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement (GlobeNewswire) +22.73%
May-26-23 07:00AM	Talaris Therapeutics Announces Leadership Transition (GlobeNewswire)
May-20-23 08:18AM	Talaris Therapeutics, Inc. (NASDAQ:TALS) most popular amongst private equity firms who own 34% of the shares, institutions hold 30% (Simply Wall St.)
Feb-16-23 03:10PM	Wellesley biotech cuts one-third of staff, explores sale (American City Business Journals) +24.05%
07:00AM	Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan (GlobeNewswire)
Dec-25-22 09:25AM	We Think Talaris Therapeutics (NASDAQ:TALS) Needs To Drive Business Growth Carefully (Simply Wall St.)
Nov-22-22 07:00AM	Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-10-22 07:00AM	Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update (GlobeNewswire) +6.99%
Nov-07-22 07:00AM	Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance (GlobeNewswire)
Oct-21-22 11:28AM	Talaris (TALS) Down on Patient Death From Renal Transplant Study (Zacks)
Oct-20-22 02:27PM	HC Wainwright Says Talaris' Technology Unprecedented In Cell Therapy Space (Benzinga) -43.39%
10:26AM	Talaris Therapeutics Reports Patient Death In Late-Stage Trial Of Experimental Drug For Graft vs Host Disease (Benzinga)
08:24AM	Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial (MarketWatch)
07:00AM	Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial (GlobeNewswire)
Oct-17-22 07:00AM	Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting (GlobeNewswire) +6.96%
Oct-04-22 07:00AM	Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-21-22 07:00AM	Talaris Therapeutics to Present at William Blairs Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event (GlobeNewswire)
Sep-06-22 07:00AM	Talaris Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +6.19%
Aug-15-22 07:00AM	Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update (GlobeNewswire)
Jul-18-22 09:47AM	We Think Talaris Therapeutics (NASDAQ:TALS) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-30-22 07:00AM	Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update (GlobeNewswire) -36.75%
Jun-07-22 04:01PM	Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022 (GlobeNewswire) -9.14%
Jun-01-22 07:00AM	Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study (GlobeNewswire)
May-31-22 07:00AM	Talaris Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +16.35%
May-17-22 04:01PM	Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +35.93% -14.51%
07:00AM	Talaris Therapeutics Announces Changes to Board of Directors (GlobeNewswire)
May-12-22 04:01PM	Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update (GlobeNewswire) -5.25%
May-02-22 07:00AM	Talaris Therapeutics Announces Upcoming Presentations at American Transplant Congress (GlobeNewswire)
Apr-28-22 11:45AM	10 Best Stocks Under $20 According to Billionaire Andreas Halvorsens Viking Global (Insider Monkey)
Apr-06-22 04:01PM	Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001 (GlobeNewswire)
Mar-22-22 04:01PM	Talaris Therapeutics to Participate at Two Upcoming Investor Conferences (GlobeNewswire) +5.50%
Mar-17-22 04:01PM	Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results (GlobeNewswire)
Feb-11-22 07:00AM	Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) -9.18%
Feb-08-22 01:32PM	We're Hopeful That Talaris Therapeutics (NASDAQ:TALS) Will Use Its Cash Wisely (Simply Wall St.)
Jan-31-22 09:38AM	Altium Wealth Management LLC Buys Vanguard FTSE Emerging Markets ETF, Invesco Variable Rate ... (GuruFocus.com)
Jan-06-22 07:00AM	Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-22 07:00AM	Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire)
Dec-20-21 07:00AM	Talaris Therapeutics Announces Addition to the Nasdaq Biotechnology Index (GlobeNewswire) +17.30%
Dec-14-21 07:00AM	Talaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney Transplant (GlobeNewswire)
Nov-30-21 07:00AM	Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma (GlobeNewswire)

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KANTOFF AARON	Director	Sep 05 '25	Option Exercise	2.08	47,890	99,526	93,281	Sep 09 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRML

Tourmaline Bio Inc

Upgrade your FINVIZ experience